• Device-related Target Lesion Failure (TLF) The composite of cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven target-lesion revascularization [ Time Frame: Within 12 months ]
  The primary endpoint will be analyzed using the Kaplan-Meier method. Hazard ratios between groups will be calculated using a Cox proportional hazard model and the primary endpoint in the two per protocol treated groups will be compared with an upper one-sided 95% confidence interval. Patients treated with the ComboTM stent will be used as the reference group.
• Target Lesion Revascularisation (TLR) [ Time Frame: Within 12 months ]
  Repeat/new revascularization (PCI or CABG) within the stent or within a 5-mm border proximal or distal to the stent. (Angina, CCS > 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR <0.80, or iFR< 0.90). TLR will be clinically driven.

• Individual components of the primary end point comprise the secondary end points [ Time Frame: Clinical follow-up will be continued through 5 years ]
  cardiac death; MI; clinically indicated TLR; all death (cardiac and noncardiac) and target vessel revascularisation (TVR); definite, probable, possible, and overall stent thrombosis according to the Academic Research Consortium definition (22); and a patient-related composite end point (all death, all MI (including procedure related MI), or any revascularization). For continuous variables, the difference between the treatment groups will be evaluated using Wilcoxon's rank-sum test. For discrete variables, the differences will be given as numbers and in percentages and will be analyzed using Fisher's exact test. Two-sided test will be used, and a pvalue of 0.05 considered significant.
• Number of participants with Cardiac Death [ Time Frame: Through 5 years ]
• Number of participants with Myocardial Infarction [ Time Frame: Through 5 years ]
  The acute MI diagnosis follows "The Joint ESC/ACCF/AHA/WHF Task Force on "Third Universal Definition of MI" (23), which has been adapted by Academy Research Consortium (22). In cases of updates of the definition of MI, the latest definition will be used.
• Target Lesion Revascularization due to clincal symptoms [ Time Frame: Through 5 years ]
  Angina, CCS > 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR <0.80, or iFR< 0.90.
• Number of patients with all cause mortality [ Time Frame: Through 5 years ]
  Cardiac and non-cardiac
• Target Vessel Revascularization due to clincal symptoms [ Time Frame: Through 5 years ]
  Angina, CCS > 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR <0.80, or iFR< 0.90.
• Number of patients with stent thrombosis [ Time Frame: Through 5 years ]
  Definite, probable, possible and overall according to the Academic Research Consortium definition (22)
• Number of patients with Patient-related composite end point [ Time Frame: Through 5 years ]
  All death, all MI (including procedure related MI) or any revascularisation

• Individual components of the primary end point comprise the secondary end points [ Time Frame: Clinical follow-up will be continued through 5 years ]
  cardiac death; MI; clinically indicated TLR; all death (cardiac and noncardiac) and target vessel revascularisation (TVR); definite, probable, possible, and overall stent thrombosis according to the Academic Research Consortium definition (22); and a patient-related composite end point (all death, all MI (including procedure related MI), or any revascularization). For continuous variables, the difference between the treatment groups will be evaluated using Wilcoxon's rank-sum test. For discrete variables, the differences will be given as numbers and in percentages and will be analyzed using Fisher's exact test. Two-sided test will be used, and a pvalue of 0.05 considered significant.
• Cardiac death [ Time Frame: Through 5 years ]
• MI [ Time Frame: Through 5 years ]
  The acute MI diagnosis follows "The Joint ESC/ACCF/AHA/WHF Task Force on "Third Universal Definition of MI" (23), which has been adapted by Academy Research Consortium (22). In cases of updates of the definition of MI, the latest definition will be used.
• Clinically indicated TLR [ Time Frame: Through 5 years ]
  Angina, CCS > 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR <0.80, or iFR< 0.90.
• All death [ Time Frame: Through 5 years ]
  Cardiac and non-cardiac
• TVR [ Time Frame: Through 5 years ]
  Angina, CCS > 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR <0.80, or iFR< 0.90.
• Stent thrombosis [ Time Frame: Through 5 years ]
  Definite, probable, possible and overall according to the Academic Research Consortium definition (22)
• Patient-related composite end point [ Time Frame: Through 5 years ]
  All death, all MI (including procedure related MI) or any revascularisation

• Combination Product: PCI with BioMatrix Alpha™ stent
  Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
  Other Name: Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
• Combination Product: PCI with Combo™ stent
  Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
  Other Name: Combined sirolimus eluting and endothelial progenitor cell Combo™ stent

• Active Comparator: Combo
  PCI with COMBO stent
  Intervention: Combination Product: PCI with Combo™ stent
• Active Comparator: BioMatrix Alpha
  PCI with BioMatrix Alpha stent
  Intervention: Combination Product: PCI with BioMatrix Alpha™ stent

Inclusion Criteria:

All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents at one of the three heart centers in Aarhus, Odense and Aalborg can be included in the study.

Exclusion Criteria:

• Age < 18 years
• The patient does not wish to participate
• The patient is not able to consent to randomization (eg. intubated patients)
• The patient do not speak Danish
• The patient is already included in the SORT OUT XI study
• Life expectancy <1 year
• Allergic to study related treatment

• Aarhus University Hospital
• Odense University Hospital
• OrbusNeich
• Biosensors International